MetaStat, Inc.
MTST
Other OTC0.00
USD
- -
- -
ISIN
US59140A2033
CUSIP
59140A203
Return %
Stock
S&P500
1Y
400.00
26.53
3Y
900.00
76.60
5Y
-96.30
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Frederick E. Pierce
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 27 Drydock Avenue Boston MA United States of America 02210
- IPO Date
- Jan 5, 2009
- Website
- metastat.com
- Similar Companies
- Business
- MetaStat, Inc. operates as a precision medicine company specializing in the research, development, and commercialization of therapeutic and diagnostic treatment solutions for cancer patients. The company primarily offers molecular diagnostic products focused on assessing the risk of systemic metastasis in epithelial-based solid tumors. Its key diagnostic platforms include MetaSite Breast, designed for early-stage invasive breast cancer patients, and MenaCalc, a tissue-based quantitative immunofluorescence assay applicable across a range of epithelial cancers such as breast, lung, colorectal, and prostate. These diagnostic tools provide oncologists with clinically actionable information regarding tumor aggressiveness and metastasis risk to guide adjuvant chemotherapy treatment decisions. Founded in 2009 and headquartered in Boston, Massachusetts, MetaStat targets the oncology healthcare market internationally. Recent major developments include ongoing efforts to advance the commercialization of its diagnostic product lines, placing emphasis on expanding the clinical adoption of MetaSite Breast and MenaCalc platforms. The company has maintained its strategic focus on precision oncology diagnostics to improve cancer patient outcomes by targeting critical metastatic pathways in solid tumors. While no recent acquisitions or funding rounds have been prominently reported in the last 1-2 years, MetaStat continues to enhance its molecular diagnostic technologies and engagement with scientific advisory boards to support its growth in precision medicine. Its business model revolves around delivering targeted, pathway-driven diagnostics to oncologists aimed at personalized cancer treatment decision-making. MetaStat’s operations encompass development and commercialization of novel cancer diagnostics, focusing on epithelial tumors with solid applications in breast and other common cancers. The company maintains a pipeline centered on refining and validating its assay platforms, supported by scientific advisory members and clinical researchers. MetaStat’s industry positioning highlights its specialization within the biotechnology and molecular diagnostics sectors, with an operational footprint oriented towards oncologists, hospitals, and diagnostic labs primarily in the United States but with potential international clinical reach. The company remains listed publicly with the ticker MTST. This description reflects MetaStat’s core business lines, key products, geographic and market focus, founding, headquarters, and the latest strategic business emphasis on diagnostic commercialization and precision oncology development as of 2025.
Metastat (OTCMKTS:MTST) vs. SNDL (NASDAQ:SNDL) Head to Head Survey